Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Picibanil Sclerotherapy for Macrocystic Lymphangioma
NCT00010452Phase 3Completed
- Sponsor
- University of Iowa
- Start
- Apr 2000
- Primary completion
- Jun 2006
- Modality
- Small Molecules, Cell Therapies, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of streptococcus pyogenes preparation in Macrocystic Lymphangioma, sponsored by University of Iowa. Primary endpoint: Efficacy of OK432 sclerotherapy versus surgical excision. Started Apr 2000; status: completed.
02
Drugs
streptococcus pyogenes preparation
03
Conditions
Macrocystic Lymphangioma
Beyond the preview
Go deeper on NCT00010452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00010452.